HC Wainwright Raises Earnings Estimates for Innate Pharma

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Analysts at HC Wainwright upped their FY2025 earnings estimates for Innate Pharma in a report issued on Thursday, September 18th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.66) for the year, up from their prior estimate of ($0.82). HC Wainwright has a “Neutral” rating on the stock. HC Wainwright also issued estimates for Innate Pharma’s FY2026 earnings at ($0.68) EPS.

A number of other analysts also recently issued reports on the stock. Leerink Partnrs downgraded shares of Innate Pharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 18th. Leerink Partners reiterated a “market perform” rating and set a $2.00 target price (down previously from $10.00) on shares of Innate Pharma in a research report on Thursday, September 18th. Finally, BTIG Research assumed coverage on shares of Innate Pharma in a research report on Monday, July 28th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $6.50.

Innate Pharma Stock Performance

NASDAQ IPHA opened at $1.82 on Monday. Innate Pharma has a 52-week low of $1.29 and a 52-week high of $3.51. The company has a 50-day simple moving average of $2.07 and a 200 day simple moving average of $2.01. The company has a debt-to-equity ratio of 3.52, a quick ratio of 2.60 and a current ratio of 2.21.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.